Floatz logo

Fludarabine

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Ohio State University Comprehensive Cancer CenterSmall moleculePhase 2Active
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

38 Active assets in the Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Ohio State University Comprehensive Cancer Center
Phase 2BBB
Imatinib
The University of Hong Kong
Phase 2BB
Tacrolimus
University of Michigan Rogel Cancer Center
Phase 2BB
Nilotinib
The University of Hong Kong
Phase 2BB
Methotrexate
University of Michigan Rogel Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

Fludarabine is also rated in:

adult T-cell leukemia/lymphomaActive
BBB
Indicative · Phase 2
76 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative · Phase 2
76 / 100
View asset →
Fanconi anemiaActive
BBB
Indicative · Phase 2/3
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →